EMEA-000980-PIP04-18
Key facts
| Invented name |
Adcetris
|
| Active substance |
Brentuximab vedotin
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0327/2018
|
| PIP number |
EMEA-000980-PIP04-18
|
| Pharmaceutical form(s) |
Powder for concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of Mature T and NK neoplasms (excluding anaplastic large-cell lymphoma and cutaneous Tcell lymphoma)
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Takeda Pharma A/S
Tel. +44 2031168000 |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|